ShareSoc webinar – Meet the analyst: Immuno-oncology

ShareSoc webinar – Meet the analyst: Immuno-oncology

Immuno-oncology is entering a new phase of innovation as first-generation checkpoint inhibitors approach clinical and commercial maturity. In our recent webinar (Redesigning immunity: The next frontier in immuno-oncology), we outline how next-generation platforms, including novel checkpoints, cancer vaccines (act as immune-priming partners) and increasingly scalable CAR-T and cell therapy approaches are designed to overcome resistance, expand responder populations and move treatment into earlier disease settings. We also discuss the approaching big pharma patent cliff (over $200bn in branded sales at risk by 2030) and the strategic and partnering implications of this shift. We outline how companies with differentiated biology and scalable technologies are best positioned to capture the next wave of value creation in oncology. The session provides a clear framework for identifying the companies best positioned to benefit from the next wave of immuno-oncology.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.